October 2026 • PharmaTimes Magazine • 4-5
6. TREATMENTS
7. COLLABORATIONS
8. CLINICAL TRIALS
9. CONDITIONS
10.The hurdles
Ten things we need to know about the Single National Formulary
20.You can call me AI
From pilots to patient impact – what healthcare needs to get right
26.Spin city
Petri dish paradox – the business of science is being failed by scientists
30.A new hope
Wales is emerging as a leading locationfor paediatric oncology trials
38.Human race
As AI becomes autonomous, ourjudgment becomes more valuable
18.Here to maternity
The technology is here. The challenge isgetting it into maternity care
24.Bold rush
Finding the real competitive advantagein pharma’s AI race
28.Pharma’s market
Pharma needs to firm up measurement todrive customer-centricity
34.Gen therapy
The clinical trials industry is embracingnext-generation FSP models
14.Sharp focus
From caution to confidence – reframingthe UK launch opportunity
16.Look who’s talking
Jess has an illuminating chat withModerna’s Emma Gilgunn-Jones
33.Event horizon!
Competitions corner: finals, deadlinesand what’s coming up
36.Arrivals and departures
Closets are cleared of their detritus onlyto be cluttered anew